These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15665414)

  • 1. Iron dysregulation and Parkinson's disease.
    Andersen JK
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S47-52. PubMed ID: 15665414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron transport in Parkinson's disease.
    Hirsch EC
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Iron homeostasis and Parkinson's disease].
    Faucheux BA; Hirsch EC
    Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():23-30. PubMed ID: 9827211
    [No Abstract]   [Full Text] [Related]  

  • 4. Chronic expression of H-ferritin in dopaminergic midbrain neurons results in an age-related expansion of the labile iron pool and subsequent neurodegeneration: implications for Parkinson's disease.
    Kaur D; Rajagopalan S; Andersen JK
    Brain Res; 2009 Nov; 1297():17-22. PubMed ID: 19699718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired iron homeostasis in Parkinson's disease.
    Double KL; Gerlach M; Youdim MB; Riederer P
    J Neural Transm Suppl; 2000; (60):37-58. PubMed ID: 11205155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies about iron in parkinsonian and control substantia nigra.
    Gałazka-Friedman J; Friedman A
    Acta Neurobiol Exp (Wars); 1997; 57(3):217-25. PubMed ID: 9407708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does cellular iron dysregulation play a causative role in Parkinson's disease?
    Kaur D; Andersen J
    Ageing Res Rev; 2004 Jul; 3(3):327-43. PubMed ID: 15231240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?
    Youdim MB
    J Neural Transm Suppl; 2003; (65):73-88. PubMed ID: 12946050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
    Youdim MB; Riederer P
    J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease.
    Salazar J; Mena N; Hunot S; Prigent A; Alvarez-Fischer D; Arredondo M; Duyckaerts C; Sazdovitch V; Zhao L; Garrick LM; Nuñez MT; Garrick MD; Raisman-Vozari R; Hirsch EC
    Proc Natl Acad Sci U S A; 2008 Nov; 105(47):18578-83. PubMed ID: 19011085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
    Weinreb O; Mandel S; Youdim MBH; Amit T
    Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.
    Gerlach M; Double KL; Ben-Shachar D; Zecca L; Youdim MB; Riederer P
    Neurotox Res; 2003; 5(1-2):35-44. PubMed ID: 12832223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential sources of increased iron in the substantia nigra of parkinsonian patients.
    Gerlach M; Double KL; Youdim MB; Riederer P
    J Neural Transm Suppl; 2006; (70):133-42. PubMed ID: 17017520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
    PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
    Wang QM; Xu YY; Liu S; Ma ZG
    Oncotarget; 2017 Jul; 8(29):47284-47295. PubMed ID: 28521299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
    Youdim MB; Ben-Shachar D; Riederer P
    Acta Neurol Scand Suppl; 1989; 126():47-54. PubMed ID: 2618593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction.
    Ben-Shachar D; Youdim MB
    J Neural Transm Suppl; 1990; 29():251-8. PubMed ID: 2193109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial ferritin suppresses MPTP-induced cell damage by regulating iron metabolism and attenuating oxidative stress.
    You LH; Li Z; Duan XL; Zhao BL; Chang YZ; Shi ZH
    Brain Res; 2016 Jul; 1642():33-42. PubMed ID: 27017962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of iron in the pathogenesis of Parkinson's disease.
    Sian-Hülsmann J; Mandel S; Youdim MB; Riederer P
    J Neurochem; 2011 Sep; 118(6):939-57. PubMed ID: 21138437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.